Tapinarof 1% QD is efficacious for the treatment of atopic dermatitis in patients with skin of color down to 2 years of age in two pivotal Phase 3 trials.

**OBJECTIVE**

To evaluate the efficacy and safety of Tapinarof (VTAMA®, Dermavant Sciences, Inc.) 1% once daily (QD) cream in children 2 years of age and older with atopic dermatitis (AD) down to 2 years of age.

**METHODS**

**Study Design**

- **Trial Design:** Double-blind, vehicle-controlled, randomized, parallel-group, pivotal Phase 3 trials conducted in patients 2-17 years of age with skin of color
- **Objective:** To evaluate the efficacy and safety of Tapinarof 1% QD cream in children 2-17 years of age with skin of color
- **Endpoints:** Efficacy and safety

**Results**

- **Efficacy**: Tapinarof demonstrated consistently high achievement of EASI75 response (Eczema Area and Severity Index score ≥75% improvement from baseline) in all skin-of-color subgroups across race categories (White, Black or African American†, Other‡, *≥75% improvement in Eczema Area and Severity Index score from baseline (EASI75) by Fitzpatrick skin type category groups, where categories IV–VI indicate patients with skin of color.)
- **Safety**: Adverse events were mostly mild or moderate and led to low rates of trial discontinuation (lower with tapinarof versus vehicle), demonstrating the predictable safety profile of tapinarof

**CONCLUSIONS**

- Tapinarof 1% QD cream is efficacious for the treatment of AD in patients down to 2 years of age, including patients with skin of color, without restrictions on duration, extent, or sites of application.

**REFERENCES**